Background
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has been associated with a reduction in transaminase level among people with hepatitis B virus (HBV) and in people with HIV (PWH), with or without HBV. It is unclear whether such reduction is due to a lower hepatotoxicity of TAF or to an enhanced suppression of HBV in people with overt or occult HBV.
Methods
We conducted a longitudinal study on PWH switching from TDF to TAF between 2016 and 2023, whose HBsAg/HBcAb status was known. A mixed-effects model with random intercepts at the patient level was used to assess the effect of the switch on transaminase levels. An interaction term between the switch and HBV status was included to evaluate whether the effect of the switch varied across three mutually exclusive HBV categories: chronic hepatitis B (CHB), defined by HBsAg+; occult HBV infection (OBI), defined as HBsAg-/HBcAb+; no HBV infection, defined as HBsAg-/HBcAb-.
Results
Among 648 PWH switching from TDF to TAF, 7.4% had CHB and 34.9% OBI. Table 1 summarizes other patient characteristics.
Switching to TAF was associated with a significant transaminase (ALT) decrease (beta [b] -3.2 UI/ml, 95%CI -4.9 to -1.5, P<0.001). Compared with patients without HBV, a significantly steeper ALT decrease upon switch was observed among those with CHB (b -7.6, 95%CI -12.3 to -2.8; P=0.002), while OBI was associated with a non-significant reduction (b -1.6; 95%CI -4.3 to 1.1; P=0.252).
In the final multivariable model, male gender (b +10.3, 95%CI 6.4 to 14.2, P<0.001) and diabetes (b +5.1, 95%CI 0.2 to 10, P=0.042) were associated with higher ALT, while older age (b -0.2 per year increase, 95%CI -0.3 to -0.1, P=0.021) and later calendar years (versus 2016-2017, b -7.1, 95%CI -13 to -1.5, P=0.012 for 2020-2023 and b -3.7, 95%CI -7.2 to -0.2, P=0.037 for 2018-2019) were associated with lower ALT. Again, a significant interaction was found between the switch and CHB versus no HBV infection (b -7.6, 95%CI -12.4 to -2.9, P=0.002) but not for OBI (b -1.5, 95%CI -4.2 to 1.2, P=0.276). Consistent results with AST were obtained.
Conclusions
Switching from TDF to TAF is associated with significant transaminase decrease in PWH. Such effect is partially dependent of HBV status, suggesting that, among those with CHB, enhanced viral suppression, not captured by plasma HBVDNA measurement, plays a role. Further studies are warranted to explore the underlying mechanisms and the long-term clinical implications of these findings.
Table or Figure
![]()